AtriCure (NASDAQ:ATRC – Get Free Report) announced its quarterly earnings data on Tuesday. The medical device company reported ($0.17) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.17), Briefing.com reports. The company had revenue of $116.27 million for the quarter, compared to analysts’ expectations of $116.24 million. AtriCure had a negative return on equity of 8.39% and a negative net margin of 9.33%. AtriCure’s revenue was up 15.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.12) earnings per share. AtriCure updated its FY 2024 guidance to -0.820–0.740 EPS.
AtriCure Stock Down 2.5 %
NASDAQ ATRC traded down $0.53 on Thursday, hitting $21.04. The stock had a trading volume of 1,207,299 shares, compared to its average volume of 787,052. AtriCure has a 52-week low of $18.94 and a 52-week high of $57.77. The business’s fifty day moving average price is $22.64 and its 200 day moving average price is $27.02. The company has a debt-to-equity ratio of 0.16, a current ratio of 4.00 and a quick ratio of 2.83. The stock has a market cap of $1.00 billion, a price-to-earnings ratio of -26.39 and a beta of 1.44.
Insider Activity
In other AtriCure news, insider Salvatore Privitera bought 5,000 shares of the company’s stock in a transaction that occurred on Thursday, May 30th. The shares were purchased at an average cost of $22.25 per share, for a total transaction of $111,250.00. Following the purchase, the insider now directly owns 103,290 shares in the company, valued at $2,298,202.50. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 3.20% of the company’s stock.
Wall Street Analyst Weigh In
Check Out Our Latest Report on AtriCure
AtriCure Company Profile
AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.
Featured Articles
- Five stocks we like better than AtriCure
- How to Invest in Insurance Companies: A Guide
- First Solar Stock: The Dawn of a New Rally in Share Prices
- Election Stocks: How Elections Affect the Stock Market
- Mastercard Stock’s Q2 Financial Results Outshine Competitors
- Find and Profitably Trade Stocks at 52-Week Lows
- Tobacco Giant’s Shares Fall on EPS Miss, Lackluster Pouch Gains
Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.